You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Ivosidenib
Ivosidenib is a potent inhibitor of mutant isocitrate dehydrogenase enzyme 1 (mIDH1), with activity against a variety of mutant IDH1 enzymes (IC50 range = 5-19 nM). Reduces intracellular 2-HG (Cat. No. 6122) by 96% at 0.5 μM. Increases sensitivity of melanoma to Temozolomide (Cat. No. 2706) in vivo and inhibits wild-type IDH1 in low magnesium and low nutrient levels. Ivosidenib also inhibits growth of tumors in cell and animal models of pancreatic cancer and inhibits invasion and migration of chondrosarcoma cells in vitro.
Technical Data for Ivosidenib
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Ivosidenib
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Ivosidenib
The following data is based on the product molecular weight 582.96. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.72 mL||8.58 mL||17.15 mL|
|5 mM||0.34 mL||1.72 mL||3.43 mL|
|10 mM||0.17 mL||0.86 mL||1.72 mL|
|50 mM||0.03 mL||0.17 mL||0.34 mL|
References for Ivosidenib
References are publications that support the biological activity of the product.
Popovici-Muller et al (2018) Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med.Chem.Lett. 9 300 PMID: 29670690
Zarei et al (2022) Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. J.Exp.Clin.Cancer Res. 41 283 PMID: 36153582
If you know of a relevant reference for Ivosidenib, please let us know.
View Related Products by Product Action
Keywords: Ivosidenib, Ivosidenib supplier, mutant, IDH1, isocitrate, dehydrogenase, potent, inhibitors, inhibits, melanoma, pancreatic, cancer, invasion, migration, Isocitrate, 1, (IDH1), 7761, Tocris Bioscience
Citations for Ivosidenib
Citations are publications that use Tocris products.
Currently there are no citations for Ivosidenib. Do you know of a great paper that uses Ivosidenib from Tocris? Please let us know.
Reviews for Ivosidenib
There are currently no reviews for this product. Be the first to review Ivosidenib and earn rewards!
Have you used Ivosidenib?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.